BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...disclosed. Some patients missed doses because several clinical sites were temporarily closed due to COVID-19. Henlius...
...biosimilar win in EU The European Commission approved Zercepac from Accord Healthcare Ltd. and Shanghai Henlius...
...Co. Mirati Therapeutics Inc. Amgen Inc. Merck & Co. U.S. Food and Drug Administration (FDA) Truvian Sciences Inc. Ascletis Pharma Inc. Shanghai Henlius...
BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

...PDCD1; CD279) - Programmed cell death 1 TNFα - tumor necrosis factor α Hongjiang Li, Staff Writer Biosimilar trastuzumab...
BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

...see “Alliance Advancing Unbranded Hyperimmune Globulin Product” ). Chinese trio join to develop antibody Shanghai Henlius...
...Biopharmaceuticals Co. Ltd. and Shanghai ZJ Bio-Tech Co. Ltd. to develop a COVID-19 antibody therapy. Henlius...
...https://www.biocentury.com/coronavirus . Elizabeth S. Eaton, Staff Writer remdesivir, GS-5734 Gilead Sciences Inc. CSL Ltd. Takeda Pharmaceutical Co. Ltd. ADMA Biologics Inc. Shanghai Henlius...
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

...IgE - Immunoglobulin E THRB - Thyroid hormone receptor β BioCentury Staff Ontruzant (Brand), SB3 (Compound #), biosimilar trastuzumab...
BioCentury | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

...EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Paul Bonanos, Associate Editor Zirabev, biosimilar bevacizumab (PF-06439535) Trazimera, biosimilar trastuzumab...
BioCentury | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

...the number of listings nearly doubled, despite a four-month lapse in new listings midyear. Shanghai Henlius...
BioCentury | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

...listings included CStone Pharmaceuticals Co. Ltd. (HKEX:2616), CanSino Biologics Inc. (HKEX:6185), Mabpharm Ltd. (HKEX:2181), Shanghai Henlius...
BioCentury | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

...Henlius Biotech Inc. (HKEX:2696) broke the lull in September, raising HK$3.2 billion in its IPO. Henlius'...
...to HK$24.3 billion since its IPO (see "Hong Kong’s First IPO in Months Values Shanghai Henlius...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...KOSDAQ:244460) 09/20/19 $25.4 $234.5 $218.3 -7% Exagen Inc. (NASDAQ:XGN) 09/18/19 $58.0 $168.5 $186.4 11% Shanghai Henlius...
BioCentury | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

...Amid market concerns due to recent Hong Kong protests, Shanghai Henlius became the first company to...
...its proposed range. Parent company Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) said Shanghai Henlius...
...sell 64.7 million shares. Henlius Biotech, which is a JV between Shanghai Fosun Pharmaceutical and Henlius...
Items per page:
1 - 10 of 79